Galecto, Inc.

Galecto is a clinical-stage biotechnology company focused on developing novel treatments for fibrosis and cancer. Founded in 2011, the company has built a strong foundation in research, focusing on the role of galectin-3 and LOXL2, two proteins involved in fibrosis and cancer development. Galecto's primary goal is to extend the healthy lifespan of patients by providing easily administered, highly efficacious, and well-tolerated treatments that significantly improve their quality of life.

Galecto's pipeline includes small molecule inhibitors that target these key proteins, leading to potential breakthroughs in treating fibrosis-related diseases and cancer. Their lead product candidate, GB1211, is an oral galectin-3 inhibitor currently in development for the treatment of decompensated cirrhosis, a serious liver condition. Galecto's dedication to innovation, backed by a strong patent portfolio, positions them as a leader in the liver therapeutics industry.

Galecto, Inc. is a clinical-stage liver therapeutics biotechnology company focused on developing a new class of medicines to treat severe liver diseases, including fibrosis, inflammation, and cancer. Their mission is to extend the healthy lifespan of patients by providing safe, effective, and well-tolerated treatments that can be easily administered, enabling long-term use and significantly improving quality of life.

Galecto promotes a culture of inclusivity and diversity, fostering a welcoming environment where individuals from various backgrounds and scientific disciplines can thrive. This commitment to diversity is reflected in its team composition, which includes over 15 nationalities and an equal gender balance. The company believes that diverse perspectives lead to higher engagement, better solutions, and increased productivity, ultimately driving its mission to bring innovative treatments to patients and improve their quality of life.

Galecto emphasizes the importance of a diverse and inclusive work environment, believing that it fosters higher engagement, better solutions, and greater productivity. They are proud to have a team representing over 15 nationalities, multiple scientific disciplines, and degrees, with an equal gender balance.